373 related articles for article (PubMed ID: 37061680)
1. Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients.
Sanoyan DA; Seipel K; Bacher U; Kronig MN; Porret N; Wiedemann G; Daskalakis M; Pabst T
BMC Cancer; 2023 Apr; 23(1):345. PubMed ID: 37061680
[TBL] [Abstract][Full Text] [Related]
2. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.
Anderson LD
Future Oncol; 2022 Jan; 18(3):277-289. PubMed ID: 34854741
[TBL] [Abstract][Full Text] [Related]
3. Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study.
Caillot L; Sleiman E; Lafon I; Chretien ML; Gueneau P; Payssot A; Pedri R; Lakomy D; Bailly F; Guy J; Quenot JP; Avet-Loiseau H; Caillot D
Transplant Cell Ther; 2024 Mar; ():. PubMed ID: 38458477
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma.
Minakata D; Ishida T; Ando K; Suzuki R; Tanaka J; Hagiwara S; Ananthakrishnan R; Kuwayama S; Nishio M; Kanda Y; Suzuki K
Int J Hematol; 2023 May; 117(5):729-737. PubMed ID: 36690910
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances in the Use of Chimeric Antigen Receptor-Expressing T-Cell Therapies for Treatment of Multiple Myeloma.
Martin T; Jackson CC; Pacaud L; Madduri D; Jagannath S
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):22-27. PubMed ID: 36411210
[TBL] [Abstract][Full Text] [Related]
6. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.
Jagannath S; Lin Y; Goldschmidt H; Reece D; Nooka A; Senin A; Rodriguez-Otero P; Powles R; Matsue K; Shah N; Anderson LD; Streetly M; Wilson K; Le HV; Swern AS; Agarwal A; Siegel DS
Blood Cancer J; 2021 Jun; 11(6):116. PubMed ID: 34145225
[TBL] [Abstract][Full Text] [Related]
7. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
Rodriguez-Otero P; Ailawadhi S; Arnulf B; Patel K; Cavo M; Nooka AK; Manier S; Callander N; Costa LJ; Vij R; Bahlis NJ; Moreau P; Solomon SR; Delforge M; Berdeja J; Truppel-Hartmann A; Yang Z; Favre-Kontula L; Wu F; Piasecki J; Cook M; Giralt S
N Engl J Med; 2023 Mar; 388(11):1002-1014. PubMed ID: 36762851
[TBL] [Abstract][Full Text] [Related]
8. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma.
Lee DH; Kumar A; Mohammed T; Peres LC; Alsina M; Bachmeier C; Blue BJ; Brayer J; Chandrasekhar S; Grajales Cruz A; De Avila G; Elmariah H; Faramand R; Freeman C; Jain M; Khadka S; Khimani F; Liu H; Nishihori T; Oswald LB; Castaneda Puglianini OA; Shain KH; Smith E; Baz RC; Locke FL; Oliveira GH; Alomar M; Hansen DK
Blood Adv; 2023 Aug; 7(16):4247-4257. PubMed ID: 37307173
[TBL] [Abstract][Full Text] [Related]
9. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium.
Hansen DK; Sidana S; Peres LC; Colin Leitzinger C; Shune L; Shrewsbury A; Gonzalez R; Sborov DW; Wagner C; Dima D; Hashmi H; Kocoglu MH; Atrash S; Simmons G; Kalariya N; Ferreri C; Afrough A; Kansagra A; Voorhees P; Baz R; Khouri J; Alsina M; McGuirk J; Locke FL; Patel KK
J Clin Oncol; 2023 Apr; 41(11):2087-2097. PubMed ID: 36623248
[TBL] [Abstract][Full Text] [Related]
10. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi NC; Anderson LD; Shah N; Madduri D; Berdeja J; Lonial S; Raje N; Lin Y; Siegel D; Oriol A; Moreau P; Yakoub-Agha I; Delforge M; Cavo M; Einsele H; Goldschmidt H; Weisel K; Rambaldi A; Reece D; Petrocca F; Massaro M; Connarn JN; Kaiser S; Patel P; Huang L; Campbell TB; Hege K; San-Miguel J
N Engl J Med; 2021 Feb; 384(8):705-716. PubMed ID: 33626253
[TBL] [Abstract][Full Text] [Related]
11. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Martin T; Usmani SZ; Schecter JM; Vogel M; Jackson CC; Deraedt W; Tian H; Yeh TM; Banerjee A; Pacaud L; Garrett A; Haltner A; Cameron C; Van Sanden S; Diels J; Valluri S; Samjoo IA
Curr Med Res Opin; 2021 Oct; 37(10):1779-1788. PubMed ID: 34256668
[TBL] [Abstract][Full Text] [Related]
12. Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial.
McGarvey N; Ung B; Carattini T; Imanak K; Lee A; Campbell TB; Patwardhan P
Adv Ther; 2023 Oct; 40(10):4626-4638. PubMed ID: 37597153
[TBL] [Abstract][Full Text] [Related]
13. Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial.
Shah N; Delforge M; San-Miguel J; Moshkovich O; Braverman J; Dhanda DS; Lanar S; Miera M; Williams A; Murphy R; Devlen J; Hege K; Campbell TB; Munshi NC
Leuk Res; 2022 Sep; 120():106921. PubMed ID: 35930999
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France.
Karampampa K; Zhang W; Venkatachalam M; Cotte FE; Dhanda D
J Med Econ; 2023; 26(1):243-253. PubMed ID: 36705644
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China.
Wu W; Ding S; Mingming Z; Yuping Z; Sun X; Zhao Z; Yang Y; Hu Y; Dong H
J Med Econ; 2023; 26(1):701-709. PubMed ID: 37145966
[TBL] [Abstract][Full Text] [Related]
16. BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma.
Fang J; Zhou F
Ann Hematol; 2024 Apr; 103(4):1069-1083. PubMed ID: 37704875
[TBL] [Abstract][Full Text] [Related]
17. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma.
Chekol Abebe E; Yibeltal Shiferaw M; Tadele Admasu F; Asmamaw Dejenie T
Front Immunol; 2022; 13():991092. PubMed ID: 36119032
[TBL] [Abstract][Full Text] [Related]
18. Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial.
Delforge M; Otero PR; Shah N; Moshkovich O; Braverman J; Dhanda DS; Lanar S; Devlen J; Miera M; Gerould H; Campbell TB; Munshi NC
Leuk Res; 2023 Jun; 129():107074. PubMed ID: 37087950
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma.
Delforge M; Shah N; Miguel JSF; Braverman J; Dhanda DS; Shi L; Guo S; Yu P; Liao W; Campbell TB; Munshi NC
Blood Adv; 2022 Feb; 6(4):1309-1318. PubMed ID: 34933328
[TBL] [Abstract][Full Text] [Related]
20. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy.
Peres LC; Oswald LB; Dillard CM; De Avila G; Nishihori T; Blue BJ; Freeman CL; Locke FL; Alsina M; Castaneda Puglianini O; Shune L; Sborov DW; Wagner C; Dima D; Hashmi H; Davis JA; Kocoglu MH; Badros AZ; Atrash S; Simmons G; Kalariya N; Ferreri C; Anderson LD; Afrough A; Kaur G; Lin Y; Liu L; Nadeem O; Voorhees P; Khouri J; McGuirk J; Sidana S; Hansen DK; Patel K
Blood Adv; 2024 Jan; 8(1):251-259. PubMed ID: 37855718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
